Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect.
Chen DM, Odueyungbo A, Csinady E, Gearhart L, Lehane P, Cheu M, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard MA, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Benichou J, Musette P, Joly P; French Study Group on Autoimmune Bullous Diseases. Chen DM, et al. Among authors: odueyungbo a. Br J Dermatol. 2020 May;182(5):1111-1119. doi: 10.1111/bjd.18482. Epub 2019 Nov 28. Br J Dermatol. 2020. PMID: 31487383 Free PMC article. Clinical Trial.
Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement.
Mellion ML, Ronco L, Berends CL, Pagan L, Brooks S, van Esdonk MJ, van Brummelen EMJ, Odueyungbo A, Thompson LA, Hage M, Badrising UA, Raines S, Tracewell WG, van Engelen B, Cadavid D, Groeneveld GJ. Mellion ML, et al. Among authors: odueyungbo a. Br J Clin Pharmacol. 2021 Dec;87(12):4658-4669. doi: 10.1111/bcp.14884. Epub 2021 May 14. Br J Clin Pharmacol. 2021. PMID: 33931884 Free article. Clinical Trial.
Quantitative muscle analysis in facioscapulohumeral muscular dystrophy using whole-body fat-referenced MRI: Protocol development, multicenter feasibility, and repeatability.
Widholm P, Ahlgren A, Karlsson M, Romu T, Tawil R, Wagner KR, Statland JM, Wang LH, Shieh PB, van Engelen BGM, Cadavid D, Ronco L, Odueyungbo AO, Jiang JG, Mellion ML, Dahlqvist Leinhard O. Widholm P, et al. Among authors: odueyungbo ao. Muscle Nerve. 2022 Aug;66(2):183-192. doi: 10.1002/mus.27638. Epub 2022 Jun 11. Muscle Nerve. 2022. PMID: 35585766
Quantitative Muscle Analysis in FSHD Using Whole-Body Fat-Referenced MRI: Composite Scores for Longitudinal and Cross-sectional Analysis.
Mellion ML, Widholm P, Karlsson M, Ahlgren A, Tawil R, Wagner KR, Statland JM, Wang L, Shieh PB, van Engelen BGM, Kools J, Ronco L, Odueyungbo A, Jiang J, Han JJ, Hatch M, Towles J, Leinhard OD, Cadavid D. Mellion ML, et al. Among authors: odueyungbo a. Neurology. 2022 Aug 30;99(9):e877-e889. doi: 10.1212/WNL.0000000000200757. Epub 2022 Jun 24. Neurology. 2022. PMID: 35750498
Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial.
Tawil R, Wagner KR, Hamel JI, Leung DG, Statland JM, Wang LH, Genge A, Sacconi S, Lochmüller H, Reyes-Leiva D, Diaz-Manera J, Alonso-Perez J, Muelas N, Vilchez JJ, Pestronk A, Gibson S, Goyal NA, Hayward LJ, Johnson N, LoRusso S, Freimer M, Shieh PB, Subramony SH, van Engelen B, Kools J, Leinhard OD, Widholm P, Morabito C, Moxham CM, Cadavid D, Mellion ML, Odueyungbo A, Tracewell WG, Accorsi A, Ronco L, Gould RJ, Shoskes J, Rojas LA, Jiang JG. Tawil R, et al. Among authors: odueyungbo a. Lancet Neurol. 2024 May;23(5):477-486. doi: 10.1016/S1474-4422(24)00073-5. Lancet Neurol. 2024. PMID: 38631764 Clinical Trial.
Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules.
Sadarangani M, Sell T, Iro MA, Snape MD, Voysey M, Finn A, Heath PT, Bona G, Esposito S, Diez-Domingo J, Prymula R, Odueyungbo A, Toneatto D, Pollard AJ; European MenB Vaccine Study Group. Sadarangani M, et al. Among authors: odueyungbo a. CMAJ. 2017 Oct 16;189(41):E1276-E1285. doi: 10.1503/cmaj.161288. CMAJ. 2017. PMID: 29038320 Free PMC article. Clinical Trial.
Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402].
Iro MA, Snape MD, Voysey M, Jawad S, Finn A, Heath PT, Bona G, Esposito S, Diez-Domingo J, Prymula R, Odueyungbo A, Toneatto D, Dull P, Pollard AJ; European Men B Vaccine Study Group. Iro MA, et al. Among authors: odueyungbo a. Vaccine. 2017 May 31;35(24):3279. doi: 10.1016/j.vaccine.2017.04.081. Epub 2017 May 5. Vaccine. 2017. PMID: 28483197 Free article. No abstract available.
Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial.
Iro MA, Snape MD, Voysey M, Jawad S, Finn A, Heath PT, Bona G, Esposito S, Diez-Domingo J, Prymula R, Odueyungbo A, Toneatto D, Dull P, Pollard AJ; European Men B Vaccine Study Group. Iro MA, et al. Among authors: odueyungbo a. Vaccine. 2017 Jan 5;35(2):395-402. doi: 10.1016/j.vaccine.2016.11.009. Epub 2016 Nov 30. Vaccine. 2017. PMID: 27914744 Free article. Clinical Trial.
Mentoring in biostatistics: some suggestions for reform.
Odueyungbo A, Thabane L. Odueyungbo A, et al. J Multidiscip Healthc. 2012;5:265-72. doi: 10.2147/JMDH.S35792. Epub 2012 Oct 15. J Multidiscip Healthc. 2012. PMID: 23093907 Free PMC article.
20 results